Stockscreener 앱 받기
4.06
1.93%
-0.08
시간 외 거래:
3.98
-0.08
-1.97%
Zentalis Pharmaceuticals Inc 주식(ZNTL)의 최신 뉴스
Zendesk Inc (ZEN) - Minichart
H.C. Wainwright Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $10 - Moomoo
H.C. Wainwright reiterates Zentalis stock rating on ovarian cancer data By Investing.com - Investing.com Canada
ZNTL Stock Price, Quote & Chart | ZENTALIS PHARMACEUTICALS INC (NASDAQ:ZNTL) - ChartMill
Zentalis Pharmaceuticals Presents Promising Phase 1b MUIR Trial Results of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 9 - Minichart
Zentalis to present ovarian cancer trial data at ASCO meeting By Investing.com - Investing.com Australia
Phase 1b ovarian cancer data for Zentalis (NASDAQ: ZNTL) azenosertib combo - Stock Titan
Zentalis Pharmaceuticals Announces Promising Phase 1b Results for Azenosertib Plus Paclitaxel in Ovarian Cancer at ASCO 2026 - Quiver Quantitative
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial - GlobeNewswire
Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026 - Yahoo Finance
Zentalis Pharmaceuticals (ZNTL) price target increased by 19.05% to 5.83 - MSN
ZNTL SEC FilingsZentalis Pharmaceuticals, Inc. 10-K, 10-Q, 8-K Forms - Stock Titan
What's behind the surge in Zentalis stock? - MSN
Immunome Inc stock (US45254C1062): oncology deal momentum keeps biotech in focus - AD HOC NEWS
A Quick Look at Today's Ratings for Zentalis Pharmaceuticals(ZNTL.US), With a Forecast Between $5 to $10 - Moomoo
Zentalis Pharmaceuticals, Inc. Stock 12‑Month Price Target Raised to $6.5, Implies 52% Upside - TradingView
Oppenheimer Maintains Zentalis Pharmaceuticals(ZNTL.US) With Buy Rating, Maintains Target Price $9 - Moomoo
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences - 富途牛牛
Zentalis: Buy Rating Reiterated as Azenosertib Strategy Advances; $10 Price Target Maintained on De-Risked Dosing and Late-Stage Catalysts - TipRanks
Zentalis Pharmaceuticals 1Q Loss/Shr 50c >ZNTL - Moomoo
TradingKey - TradingKey
Is Zentalis Pharmaceuticals (ZNTL) Attractive After Q1 2026 Earn - GuruFocus
ZNTL Advances Key Trials for Ovarian Cancer Treatment - GuruFocus
ZNTL: Azenosertib shows >30% ORR in Cyclin E1-positive PROC, targeting a major unmet need - TradingView
Zentalis Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Zentalis Advances Azenosertib with New Trial Updates - TipRanks
Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress - The Manila Times
Zentalis (ZNTL) trims Q1 loss as azenosertib moves into Phase 3 - Stock Titan
Zentalis Pharmaceuticals, Inc. 1Q 2026: Net income $(35.4)M, EPS $(0.50) — 10-Q Summary - TradingView
Zentalis (Nasdaq: ZNTL) trims Q1 2026 loss while pushing azenosertib toward pivotal ovarian cancer milestones - Stock Titan
Press Release: Zentalis Pharmaceuticals Reports First Quarter 2026 Financial Results and Clinical Progress - Moomoo
Zentalis Pharmaceuticals Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
Zentalis begins phase 3 trial of ovarian cancer drug By Investing.com - Investing.com South Africa
Zentalis Starts Pivotal Phase 3 ASPENOVA Ovarian Cancer Trial - TipRanks
Zentalis begins phase 3 trial of ovarian cancer drug - Investing.com
Zentalis Pharmaceuticals Announces First Patient Dosed in ASPENOVA Phase 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer - The Manila Times
Zentalis starts global Phase 3 ovarian cancer trial against chemotherapy - Stock Titan
Zentalis doses first patient in Phase 3 ASPENOVA trial for Cyclin E1-positive PROC - TradingView
Phase 3 ovarian cancer trial starts for Zentalis (Nasdaq: ZNTL) drug azenosertib - Stock Titan
Zentalis Pharmaceuticals Announces First Patient Dosed in - GlobeNewswire
Zentalis Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(4) - marketscreener.com
Zentalis Pharmaceuticals Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
New Zentalis hire gets 26,000 stock options at $4.09 a share - Stock Titan
[ARS] Zentalis Pharmaceuticals, Inc. SEC Filing - Stock Titan
Zentalis (ZNTL) schedules 2026 virtual meeting on directors, auditor and executive pay - Stock Titan
Zentalis Pharmaceuticals (ZNTL) Price Target Decreased by 14.14% to 5.42 - MSN
ZNTL Should I Buy - Intellectia AI
Zentalis Pharmaceuticals Announces Abstract Acceptance at ASCO 2026 Featuring Azenosertib in Combination with Paclitaxel for Platinum-Resistant Ovarian Cancer - The Manila Times
Zentalis Pharmaceuticals Announces Abstract Acceptance at - GlobeNewswire
Zentalis (ZNTL) Locks In Its Cancer Drug Dose; Jefferies Raises the Target - Insider Monkey
2.98%
1.33%
자본화:
|
볼륨(24시간):